Big Pharma Split Corp.

QUARTERLY PORTFOLIO DISCLOSURE

as at March 31, 2018

Total Assets

The total asset of the Big Pharma Split Corp. was \$31,307,818 and includes the value of the Preferred Shares.

Summary of Investment Portfolio

Sector Allocation	% of Total Assets
Pharmaceuticals	81.3
Biotechnology	17.5
Total Portfolio Assets	98.8
Cash and other assets and liabilities	1.2
Total Asset Value	100.0

Portfolio Allocation	% of Total Assets
Common Shares	68.5
ADR	30.8
Equity Option	(0.5)
Total Portfolio Assets	98.8
Cash and other assets and liabilities	1.2
Total Asset Value	100.0

Portfolio Breakdown

Top Holdings	% of Total Assets
GlaxoSmithKline PLC ADR	10.8
AstraZeneca PLC ADR	10.8
Merck & Co., Inc.	10.2
Sanofi ADR	10.2
Eli Lilly and Company	10.1
Pfizer Inc.	10.0
Johnson & Johnson	9.9
Bristol-Myers Squibb Company	9.7
Amgen Inc.	9.3
AbbVie Inc.	8.3
Cash and other assets and liabilities	1.2
Equity Options	(0.5)

The summary of investment portfolio may change due to ongoing portfolio transactions of the investment fund. This quarterly update is available on our website at www.harvestportfolios.com.

 Customer Service
 Address

 710 Dorval Drive

 416.649.4541
 Suite 209

 Toll: 1.866.998.8298
 Oakville, ON

 L6K 3V7

